Relay Therapeutics Inc
General ticker "RLAY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $643.4M
Relay Therapeutics Inc does not follow the US Stock Market performance with the rate: -21.5%.
Estimated limits based on current volatility of 3.9%: low 4.08$, high 4.41$
Factors to consider:
- Current price 32.5% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [6.43$, 15.54$]
- 2024-12-30 to 2025-12-30 estimated range: [7.41$, 16.86$]
Financial Metrics affecting the RLAY estimates:
- Negative: Non-GAAP EPS, $ of -2.80 <= 0.10
- Negative: Operating profit margin, % of -93.59 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -20.52 <= 2.35
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
Short-term RLAY quotes
Long-term RLAY plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $3.03MM | $1.38MM | $25.55MM |
| Operating Expenses | $367.73MM | $300.66MM | $398.55MM |
| Operating Income | $-364.70MM | $-299.27MM | $-373.00MM |
| Non-Operating Income | $0.83MM | $8.77MM | $31.03MM |
| R&D Expense | $172.65MM | $246.35MM | $330.02MM |
| Income(Loss) | $-363.87MM | $-290.51MM | $-341.97MM |
| Taxes | $132.94MM | $-36.25MM | $0.00MM |
| Profit(Loss) | $-496.81MM | $-254.26MM | $-341.97MM |
| Stockholders Equity | $897.81MM | $950.22MM | $752.00MM |
| Inventory | $682.49MM | $12.11MM | $0.00MM |
| Assets | $1,008.44MM | $1,099.77MM | $843.98MM |
| Operating Cash Flow | $-74.41MM | $-229.49MM | $-300.32MM |
| Capital expenditure | $3.47MM | $9.06MM | $4.13MM |
| Investing Cash Flow | $-479.51MM | $-188.75MM | $257.63MM |
| Financing Cash Flow | $388.09MM | $289.91MM | $34.75MM |
| Earnings Per Share* | $-5.22 | $-2.27 | $-2.79 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.